NCT02439359

A Placebo-Controlled, Dose-Escalating Study to Examine the Safety and Tolerability of Single Intravenous Doses of CF-301 in Healthy Subjects

A Phase 1, Placebo-Controlled, Dose-Escalating Study to Examine the Safety and Tolerability of Single Intravenous Doses of CF-301 in Healthy Male and Female Subjects

• Status: Completed
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 20 (actual)
• Sponsor: ContraFect · Industry
• Sex: All
• Age: 18 Years – 55 Years
• Healthy volunteers: Accepted

Summary

A Phase 1, Placebo-Controlled, Dose-Escalating Study to Examine the Safety and Tolerability of Single Intravenous Doses of CF-301 in Healthy Subjects.

Conditions

• Staphylococcus Aureus Bloodstream Infections (BSI; Bacteremia)

Interventions

Type	Name	Description
DRUG	CF-301	Dose escalation
DRUG	Placebo

Timeline

• Start date: 2015-05-01
• Primary completion: 2015-12-01
• Completion: 2015-12-01
• First posted: 2015-05-08
• Last updated: 2020-04-07

Locations

2 sites across 1 country: United States